Based on our research, we estimate that the global investigative site community spent $170 million in 2024 to complete ...
Gazyva/Gazyvaro (obinutuzumab) was found to significantly improve complete renal response in lupus nephritis patients, ...
In an interview with Applied Clinical Trials Associate Editor Don Tracy, Richard Young, CEO, Cluepoints, offers his key ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback